Vilhelm Wessman

Part of Celtic Holdings SCA, Alvogen Lux Holdings SARL is a Luxembourger company that manufactures generic pharmaceutical products. The company is based in Nidderaanwen, Luxembourg. The CEO of the company is Vilhelm Róbert Wessman.

Alvogen, Inc. develops, manufactures, and distributes generic pharmaceutical products. The firm's business include product development, contract manufacturing and research, sales of generic medicines, bio-similar, and over the counters. Its product portfolio consists of molecules for the treatment of conditions in the fields of oncology, cardiology, respiratory, neurology and gastroenterology. The company was founded by Robert Wessman in 2009 and is headquartered in Pine Brook, NJ.

Alvogen Iceland ehf develops, manufactures and distributes generic pharmaceutical products. It offers Eradizol, Kalmente, Eubiotic, Windi, Zinkspray, and Aftamed. The company was founded in 2010 and is headquartered in Reykjavik, Iceland.

Alvogen Pharma US, Inc. engages in the development, manufacturing and distributing generic, brand, over-the-counter brands and biosimilar products. The company was founded in March 2012 and is headquartered in Morristown, NJ.

Alvotech hf operates as a biotech company. It is focused on the development and manufacture of biosimilar medicines for patients. The company’s products help in treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech was founded by Robert Wessman in 2013 and is headquartered in Reykjavík, Iceland.

Part of Alvotech, Alvotech Holdings SA is a Luxembourger biopharmaceutical company that specializes in developing and manufacturing high-quality, cost-competitive biosimilars to improve the availability and accessibility of biologic medicines to patients worldwide. The company is based in Luxembourg, Luxembourg. Alvotech is committed to social responsibility, caring about the wellbeing of the community, patients, partners, and employees. The company is led by science, driven by passion, and committed to broadening the availability and access of biosimilars. The company was founded in 2018. Alvotech Holdings was acquired by Oaktree Acquisition Corp. II on June 15, 2022 for $2,249.28 million.

Part of Celtic Holdings SCA, Alvogen Emerging Markets Holdings Ltd. is a Chinese pharmaceutical company that offers high-quality, affordable generic medications to reduce healthcare costs globally. The company is based in Wanchai, Hong Kong. The company's growth strategy is fueled by a unique portfolio of high-quality and difficult-to-make pharmaceutical products. Alvogen's sister company, Alvotech, specializes in the development and manufacturing of high-quality biosimilar medicines. The company was founded in 2009 by Vilhelm Róbert Wessman, who has been the CEO since 2009.

Adalvo Ltd. is a pharmaceutical company with headquarters in an undisclosed location and additional offices in over 15 countries. The private company is based in an undisclosed location and has subsidiaries in over 15 countries, including the United States and India. The Maltese company takes a unique and customized approach to help its partners achieve their business goals in the dynamic pharmaceutical sector. Adalvo is committed to accelerating the growth and development of its employees and local communities while striving for excellence in all its endeavors. The company's purpose-driven culture is focused on improving the lives of patients worldwide. Adalvo has a dynamic leadership team with significant experience and industry know-how. The CEO of the company is Anil Okay.

Aztiq Pharma Partners SARL is an investment holding Luxembourger company. The private company is based in Senningerberg, Luxembourg.

Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ.